Photofrin has the potential to eclipse every CXR drug. Most people don't realize what a blockbuster drug Photofrin is. It has the potential to be applied to many different cancers. But the most exciting of all is in the pulmonary area namely success in the field of Mesothelioma ....since it is so prevalent throughout the world. Globally much largest population with Mesothelioma than Cholangiocarcinoma, and if it proves to extend and save life as it has with other Photofrin treatments, then sky is the limit.
Anyway here are the transcript from what was said about Photofrin by MT and EB.
On January 20th 2016 cc in Kelowna - Mark Thompson
Phototofrin is our main development asset, we'll spend about 5% of our revenue this year on R&D. We have a phase 3 trial going on Cholangiocarcinoma (bile duct cancer). That product can be about a 100m dollar product if it works out well. It's a standard of care right now in Germany. We're very excited about that product, but frankly we don't get a lot of credit for it, so we're going to continue to work away, and hopefully it will live up to what our expectations are.
On March 24th 2016 Q4 and 2015 CC- Ed Borkowsi
For our Orphan segment, we are running a clinical trial for PDT with Photofrin to evaluate its safety and efficacy as a potential treatment for cholangiocarcinoma. We are also supporting investigator-initiated trials for indications such as mesothelioma. In addition, we continue to evaluate and develop new applications for Photofrin and plan to expand product sales into new geographic areas, utilizing our new platform, which we expect will create additional new revenue.
Sent from my iPad